Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial-Reference-Cited by-同舟云学术

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Published:2019-04-10 Issue:10 Volume:120 Page:959-967
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ribi Karin, ,Luo Weixiu,Colleoni Marco,Karlsson Per,Chirgwin Jacquie,Aebi Stefan,Jerusalem Guy,Neven Patrick,Di Lauro Vincenzo,Gomez Henry L.,Ruhstaller Thomas,Abdi Ehtesham,Biganzoli Laura,Müller Bettina,Barbeaux Annelore,Graas Marie-Pascale,Rabaglio Manuela,Francis Prudence A.,Foukakis Theodoros,Pagani Olivia,Graiff Claudio,Vorobiof Daniel,Maibach Rudolf,Di Leo Angelo,Gelber Richard D.,Goldhirsch Aron,Coates Alan S.,Regan Meredith M.,Bernhard Jürg

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0435-4.pdf

Reference26 articles.

1. Sabnis, G. J., Macedo, L. F., Goloubeva, O., Schayowitz, A., Brodie, A. M. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68, 4518–4524 (2008).

2. Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G. et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 127–138 (2018).

3. Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., Howell, A. et al. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res. Treat. 100, 273–284 (2006).